S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Pediapharm Inc. (PDP.V) Stock Forecast, Price & News

+0.01 (+1.69 %)
(As of 12/18/2018)
Today's Range
Now: C$0.30
50-Day Range
MA: C$0.30
52-Week Range
Now: C$0.30
Volume26,000 shs
Average Volume100,369 shs
Market CapitalizationC$66.36 million
P/E RatioN/A
Dividend YieldN/A
Pediapharm Inc. operates as a specialty pharmaceutical company in Canada. It distributes prescription medicines that are used to treat pathological conditions, which primarily affect children from infancy to 18 years of age; and commercializes non-prescription products, such as non-prescription drugs and medical devices that fulfill unmet medical needs of children. The company was incorporated in 2003 and is headquartered in Verdun, Canada.


Overall MarketRank

0.50 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesC$11.16 million
Cash FlowC$0.01 per share
Book ValueC($0.01) per share



Market CapC$66.36 million
Next Earnings DateN/A
+0.01 (+1.69 %)
(As of 12/18/2018)
30 days | 90 days | 365 days | Advanced Chart

Receive PDP News and Ratings via Email

Sign-up to receive the latest news and ratings for PDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Pediapharm Inc. (PDP.V) (CVE:PDP) Frequently Asked Questions

What stocks does MarketBeat like better than Pediapharm Inc. (PDP.V)?

Wall Street analysts have given Pediapharm Inc. (PDP.V) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pediapharm Inc. (PDP.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Is Pediapharm Inc. (PDP.V) a good dividend stock?

Pediapharm Inc. (PDP.V) pays an annual dividend of C$0.14 per share and currently has a dividend yield of 0.00%.
View Pediapharm Inc. (PDP.V)'s dividend history.

Who are some of Pediapharm Inc. (PDP.V)'s key competitors?

What other stocks do shareholders of Pediapharm Inc. (PDP.V) own?

Who are Pediapharm Inc. (PDP.V)'s key executives?

Pediapharm Inc. (PDP.V)'s management team includes the following people:
  • Mr. Sylvain Chretien, Pres, CEO & Director (Age 54)
  • Mr. Roland Boivin, Chief Financial Officer
  • Mr. Richard Labelle, VP of Sales & Marketing
  • Mr. Benoît Hébert, VP of Bus. Devel. & Licensing (Age 50)
  • Mr. Normand Chartrand, Consultant (Age 59)

What is Pediapharm Inc. (PDP.V)'s stock symbol?

Pediapharm Inc. (PDP.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "PDP."

How do I buy shares of Pediapharm Inc. (PDP.V)?

Shares of PDP and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What is Pediapharm Inc. (PDP.V)'s stock price today?

One share of PDP stock can currently be purchased for approximately C$0.30.

How big of a company is Pediapharm Inc. (PDP.V)?

Pediapharm Inc. (PDP.V) has a market capitalization of C$66.36 million and generates C$11.16 million in revenue each year.

What is Pediapharm Inc. (PDP.V)'s official website?

The official website for Pediapharm Inc. (PDP.V) is www.pedia-pharm.com.

How can I contact Pediapharm Inc. (PDP.V)?

Pediapharm Inc. (PDP.V)'s mailing address is 1 du Commerce Pl Suite 225, VERDUN, QC H3E 1A2, Canada. The company can be reached via phone at +1-514-7622626.

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.